AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00422461
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral, tablets, once daily, for 28 days
Trial: NCT03548415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously.
Trial: NCT01454063
Drug: OMS302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Trial: NCT01454063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Trial: NCT05125627
Drug: Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
Trial: NCT03010865
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
Trial: NCT03142451
Drug: FMX103 minocycline foam 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Trial: NCT00370136
Drug: ultrasound contrast
RxNorm normalized name: ULTRASOUND CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00337194
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03631121
Drug: Basalin to Lantus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
Trial: NCT02018887
Drug: LY2969822
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT02018887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT00005940
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005940
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02920567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
Trial: NCT00499538
Drug: SKI-606
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02491060
Drug: IDP-121 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product: IDP-121 Lotion
Trial: NCT02491060
Drug: IDP-121 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Product: IDP-121 Vehicle Lotion
Trial: NCT00201773
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
Trial: NCT00708006
Drug: HGS1029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
Trial: NCT00281580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Telmisartan and Amlodipine once daily for eight weeks
Trial: NCT00404300
Drug: Optivate
RxNorm normalized name: Optivate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived Factor VIII
Trial: NCT01694186
Drug: FAI insert
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005684
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00926705
Drug: Dexmedetomidine and Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
Trial: NCT00926705
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
Trial: NCT00671502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT01168531
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin B complex formula
Trial: NCT00191152
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
Trial: NCT02358395
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered continuously twice daily with doses separated by 9-15 hours.
Trial: NCT00445120
Drug: Lactobacillus Rhamnosus GG
RxNorm normalized name: Lactobacillus rhamnosus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
Trial: NCT00445120
Drug: placebo (sugar)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to patients once daily for six months
Trial: NCT00047268
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01935154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00976300
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
Trial: NCT00083109
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03193307
Drug: Microgynon® 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run in period \& Treatment Period
Trial: NCT00502515
Drug: SSR180575
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily dosing
Trial: NCT00502515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily dosing
Trial: NCT02846428
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at 900 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Trial: NCT02846428
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Trial: NCT02273466
Drug: Desipramine tablet
RxNorm normalized name: desipramine Oral Tablet
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02273466
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00881244
Drug: AS1411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.v. 4-7 days, 1-40 mg/kg/day
Trial: NCT03093168
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 40mg/kg
Trial: NCT00986895
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
Trial: NCT02644811
Drug: Topical anesthesia (buccal and palatal)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
Trial: NCT02644811
Drug: Topical anesthesia (buccal)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
Trial: NCT02509299
Drug: Standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Trial: NCT04536532
Drug: HEC121120 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Trial: NCT02268851
Drug: TGR-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken whole daily with water and with food
Trial: NCT02370693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
Trial: NCT02922660
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
Trial: NCT03599466
Drug: Zestril Tab 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zestril Tab 20mg will be used as a reference drug in this study
Trial: NCT01864096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
Trial: NCT04536532
Drug: HEC121120 placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Trial: NCT03879577
Drug: FEC
RxNorm normalized name: Fectrim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
Trial: NCT03879577
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to all premenopausal patients.
Trial: NCT01903200
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01639521
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01639521
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00294567
Drug: Calcium channel blockers (amlodipine, azelnidipine)
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: amlodipine Drug: azelnidipine
Trial: NCT01959971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous
Trial: NCT00537082
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 6 months
Trial: NCT00537082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 6 months
Trial: NCT00773110
Drug: 20% Human albumin solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
Trial: NCT00773110
Drug: Gelofusin
RxNorm normalized name: Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
Trial: NCT03850301
Drug: XBD173
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days treatment
Trial: NCT02793778
Drug: CROWN Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
Trial: NCT03769168
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
Trial: NCT00260390
Drug: Testoviron
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04607785
Drug: Miswak mouthwash group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for seven days for two months
Trial: NCT02569905
Drug: flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flurbiprofen 50mg
Trial: NCT04026451
Drug: Deep sedation with propofol andfentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
Trial: NCT01902303
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual micro dosing of placebo for 7 days
Trial: NCT04682964
Drug: Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
Trial: NCT01699685
Drug: QAB149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Trial: NCT01699685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Trial: NCT01699685
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Trial: NCT03189511
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg twice daily per mouth for 14 days.
Trial: NCT00553306
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002482
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03112187
Drug: Iron Supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
Trial: NCT01161121
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
Trial: NCT00598975
Drug: NKTR-102 100 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled.
Trial: NCT03718403
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline will be given to maintain a peak level between 10-15 mcg/mL
Trial: NCT00252889
Drug: Topotecan and pegylated doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
Trial: NCT00983957
Drug: Ortho Tri-Cyclen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, once daily, 78 days
Trial: NCT02500342
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Trial: NCT02500342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Trial: NCT01745302
Drug: TCM
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
Trial: NCT01210911
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
Trial: NCT02327247
Drug: PLENDIL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended Release Tablets, 10mg
Trial: NCT04488419
Drug: ATH-1017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe